

# Freedom to Live Life Fully



A Global Leader in Large-  
Volume Subcutaneous  
Drug Delivery

Nasdaq: KRMD

Corporate Overview

May 2026

# Forward Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. All statements that are not historical fact are forward-looking statements.

Forward-looking statements discuss the Company's current expectations and projections relating to its plans, objectives, future performance, business, outlook and financial projections. Forward-looking statements can be identified by words such as "goals", "expected", "plan", "drivers", "pathway", "milestones", "opportunities" and "outlook", and include without limitation SCIg forecasted market growth, anticipated PFS conversions, financial guidance for 2026, long-term financial goals, number and timing of new drug additions, timing of 510(k) and global submissions and approvals, timing of entry into oncology market, pathway to 20% growth, timing of entry into new markets, timing of new pharma collaborations, and predicted launch with prefilled syringe (PFS) in targeted markets. Actual results may differ materially from the results predicted, and reported results should not be considered as an indication of future performance.

The potential risks and uncertainties that could cause actual results to differ from the results predicted include, among others, uncertainties associated with success of pharma collaborations, actual SCIg market growth, prefilled syringe penetration, plasma supply, clinical trial activity and success, approval and commercialization of new drug indications, the shift to increased healthcare delivery in the home, new patient diagnoses, customer ordering patterns, global health crises, innovation and competition, labor and supply price increases, inflationary impacts, labor supply, tariffs and those risks and uncertainties included under the captions "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2025, which is on file with the SEC and available on our website at [www.korumedical.com/investors](http://www.korumedical.com/investors) and on the SEC website at [www.sec.gov](http://www.sec.gov). All information provided in this release and in the attachments is as of May 27, 2026, unless otherwise indicated. Undue reliance should not be placed on the forward-looking statements in this press release, which are based on information available to us on the date hereof. We undertake no duty to update this information unless required by law.

Revenues: All references to revenue(s) in this presentation refer to net revenues.

# We enable, simplify, and enhance the delivery of large-volume subcutaneous (LVSC) drugs in the home and in the clinic

## More Time For What Matters Most



KORU's Freedom Infusion System is a **global leader in large-volume (>10mL) drug delivery**

**Capitalizing on the ongoing shift** from intravenous (IV) hospital settings to **subcutaneous (SC) therapy in the home and in infusion clinics**

Our subcutaneous Freedom Infusion System is, today, primarily used by **~60,000 chronic, recurring** subcutaneous immunoglobulin (SCIg) drug therapy patients

**Expanding our market beyond SCIg** via 9 current collaborations with pharmaceutical companies to bring **new drug therapies** onto our label

**Leveraging a low cost go-to-market model** by serving pharmaceutical companies, specialty pharmacies, home care networks, and distributors

# Our Company KORU at a Glance



FREEDOM INTEGRATED INFUSION SYSTEM  
~60k Global Patients



DRUG CLEARANCES / REGISTRATIONS  
**9 Drugs / 30+ Countries**  
First Subcutaneous Drug Clearance 2010




FY 2025 REVENUE  
**\$41.1M<sup>1</sup>; 22% y/y growth**  
~75%+ Recurring revenue  
~3% OpEx increase



\$10M UNDRAWN DEBT FACILITY IN PLACE  
**\$8.8M Cash Balance<sup>1</sup>**




HEADQUARTERS/MANUFACTURING  
**Mahwah, NJ**



FY2025 REVENUES  
**\$41.1M**

- Domestic Core
- International Core
- Pharma Services & Clinical Trials



Pharmaceutical drug collaborations move to Core business following 510(k) clearance for use of the drug with the KORU Freedom Infusion System

# KORU's Freedom Infusion System

## Mechanical Pumps

~20% of revenues




**Freedom60**  
INFUSION SYSTEM




**FreedomEDGE**  
INFUSION SYSTEM

## Customizable Consumables

~80% of revenues



**Precision**  
FLOW RATE TUBING



**High-Flo**  
SUBQ NEEDLE SET



Simple, Easy-to-use,  
Reusable mechanical  
pump



9 On-label  
SC drugs<sup>1</sup>



2.7M+ annual infusions,  
~60k recurring chronic  
patients  
(ages 6-93)



97% Patient  
adherence rate<sup>2</sup>




Customizable  
platform for use  
with large-volume  
SC drugs



Registered in  
36 countries

# The Movement of Healthcare from Hospital to the Home Driving Large and Growing Subcutaneous Infusion Opportunity



## KORU'S Strategic Growth Pillars




Our Opportunity

# Shift from IV to SC is Driving a Sizeable and Growing Market of Large-Volume Subcutaneous (LVSC) Opportunities

Primarily SCIg Drugs with KORU Freedom Infusion System

Primarily Oncology Drugs with Manual Push Syringe




7 LVSC drugs have launched between 2010-2019, 6 of which were in the Ig drug class and approved with the KORU Freedom Infusion System

Between 2020-2026, 13 drugs have launched, and the LVSC market has diversified, primarily in oncology

There are 95+ new drugs in the clinical pipeline as pharma companies are increasingly adding SC formulations

- On label w/KORU Freedom Infusion System
- On label w/on-body infusion device
- Drugs administered with manual push syringe
- Drugs administered with e-pump system
- ⋮ Pre-Commercial<sup>2</sup>
- In Clinical Development

# Global Ig Business Drives Annual Recurring Revenue Base



■ **20% Market penetration**  
Ig is only 20% penetrated by SC (vs 80% IV); significant room for growth

■ **8-10% Market growth<sup>2</sup>**  
SCIg Market is growing 8-10% year globally; new patients begin treatment protocol annually

■ **≈\$750-\$1,000 Annual revenue per patient**  
Recurring revenue generated by each Ig patient on the KORU Freedom Infusion System; based on 1x pump sales + weekly consumables

# Pipeline Opportunities in SCIg and New Drug Therapies

8 in Pipeline

9 on Label

## Active Opportunities for New Drugs and Indications<sup>1</sup>

Commercial

Phase III

Phases I & II

Drug Asset	Annual Global Infusions Estimate <sup>3</sup>
Deferoxamine <sup>2</sup> ★	200k
Phesgo®	1.1M
+	
Empaveli® FSGS & DGF ★	25K + 25K
Endocrinology Drug ★	500k
Nephrology Drug	600k
+	
Respiratory Drug	1M
ForCast Orthopedics	140k
Multi-Indication Drug	2.4M

Estimated KRMD Launch 0-1 Yr<sup>1</sup>

Estimated KRMD Launch 1-3 Yrs<sup>1</sup>

Estimated KRMD Launch 3-5 Yrs<sup>1</sup>

Represents >6M total annual infusions worldwide

## Drugs on KORU's Freedom Infusion System's Label

SCIg

5.4M<sup>3</sup> Annual Infusions



6 Ig Collaborations for expanded indications and devices fuel share gains

Non-SCiG

<0.25M<sup>3</sup> Annual Infusions



2 Non-Ig Drugs broadening platform<sup>4</sup>

★ Update since prior quarter. 1. Clearance dates are based on most recent estimation and are subject to change, 2. KRMD pursuing drug label independently 3. Annual infusion figures are estimates based on total patient population and dosing schedule. Not adjusted for clinical risk, 4. Empaveli® is the U.S. brand name, outside of the U.S. the therapy is marketed as Aspaveli®

# Strategic Oncology Infusion Market Entry Initiative Progressing to Plan

Currently 7 Subcutaneous Oncology Drugs Available on the Market Using Syringe Manual Push

**DARZALEX Faspro<sup>®</sup>**  
(daratumumab and hyaluronidase-fihj)  
Injection for subcutaneous use | 1,800mg/30,000units

**KEYTRUDA Qlex<sup>™</sup>**  
pembrolizumab + bereahyaluronidase alfa-pmph  
Subcutaneous Injection | 165 mg + 2,000 units/mL

**PHESGO<sup>®</sup>**  
pertuzumab/trastuzumab/hyaluronidase-zzxf  
SUBCUTANEOUS INJECTION | 1,200 mg/240 units + 1,600 mg/320 units

**OPDIVO Qvantig<sup>™</sup>**  
nivolumab + hyaluronidase-nvhy  
SUBCUTANEOUS INJECTION | 120 mg + 2,000 units / mL

**TECENTRIQ Hybreza<sup>™</sup>**  
atezolizumab/hyaluronidase-tajs  
SUBCUTANEOUS INJECTION 1875 mg/30,000 units

**Herceptin HYLECTA<sup>™</sup>**  
trastuzumab and hyaluronidase-oysk  
INJECTION FOR SUBCUTANEOUS USE | 600 mg/10,000 units

**RituxanHYCELA<sup>®</sup>**  
rituximab/hyaluronidase human | 1,400 mg/23,400 units  
subcutaneous injection | 1,600 mg/26,800 units

~\$138M  
2030<sup>1</sup> TAM



~\$60M  
Oncology Infusion Pump & Consumables  
2025<sup>1</sup> TAM


Successful US Pilot Study Validated Value Proposition for KORU Freedom System in Infusion Clinics

- ✓ 100% of doses successfully administered
- ✓ ~70% of nurses reported ability to multitask, improving workflow efficiency
- ✓ High Nurse (4.8/5) and Patient (4.9/5) Satisfaction



# Financial Highlights

Revenue (\$M)



	1Q 2026	1Q 2025	Y/Y Δ
<b>Revenue</b>	\$11.8M	\$9.6M	22% Growth
<b>Gross Margin</b>	61.5% <sup>1</sup>	62.8%	130bps Decrease
<b>OpEx</b>	\$8.1M	\$7.3M	11% Increase
<b>Net Loss</b>	(\$0.8M)	(\$1.2M)	33% Improvement
<b>Adj. EBITDA*</b>	(\$0.01M)	(\$0.2M)	95% Improvement
<b>Cash Usage</b>	(\$0.1M)	(\$0.7M)	86% Improvement

# Strategically Positioned for Accelerated Growth

## Strong Fundamentals, Significant Opportunity<sup>1</sup>

Large and growing market for SC drug delivery; ~95 >10mL drugs in development

Leading share in U.S. SCIg, gaining momentum internationally

~60,000 recurring revenue patients on platform

~8 non-Ig pipeline drugs with RYSTIGGO<sup>®2</sup> and Phesgo<sup>®</sup> as near-term commercial opportunities

## Recent Accomplishments<sup>1</sup>

22% 1Q26 revenue growth over prior year period

Gross margins consistently >60%

1Q26 cash usage of \$0.1M; 86% y/y improvement

1Q26 Adj. EBITDA of (\$0.01M) ; 95% y/y improvement

## Long Term Financial Goals<sup>3</sup>


\$100M revenue

Accelerated double-digit revenue CAGR

>65% gross margins

+20% EBITDA margin

# Sustained Pathway to +20% Growth



## Key Growth Drivers

- Sustained share of SCIG market growth and share gains**  
8-10% annual growth
- New product launches & innovation**  
2<sup>nd</sup> generation consumables, new PFS pump, and flow controller
- Entry into new SCIG markets, expansion of established markets, vial to PFS conversions**
- New drugs on label**  
Includes current pipeline

# Adam Kalbermatten Appointed CEO

*effective July 1, 2026*



Linda Tharby  
CEO through June 30<sup>th</sup>  
BOD through Dec. 31<sup>st</sup>



Adam Kalbermatten, CCO  
President effective March 15<sup>th</sup>  
CEO effective July 1<sup>st</sup>  
**20+** years MedTech/Pharma experience



Tom Adams, CFO  
**25+** years of  
MedTech/Pharma  
experience



Eric Schiller, CTO  
**25+** years  
of MedTech/Pharma  
experience



Chris Pazdan, COO  
**19+** years  
of MedTech/Pharma  
experience



Brent Rutland, VP of  
Global Medical Affairs  
**25+** years  
of MedTech/Pharma  
experience

## >115 Years of MedTech and Pharma Experience Among Retained Leadership

- Linda Tharby retiring as CEO effective June 30, 2026
  - Will remain on Board of Directors through December 31, 2026
- Adam Kalbermatten assumed role of President effective March 15, 2026, CEO Officer effective July 1, 2026
- Leadership team with extensive institutional knowledge across medical device and pharmaceutical industries



# Execution Milestones on Path to Accelerated Revenue Growth

## Reiterating 2026 Financial Guidance<sup>1</sup>

- 15-22% revenue growth
- Positive Adjusted EBITDA and positive cash flow

## Enable More Drugs, Reach More Patients

- Add 4 new pipeline collaborations for FY26: 2 of 4 complete
- ✓ Deferoxamine 510(k) submitted in Q1 2026

## Expand Internationally

- ✓ Freedom60 EU MDR clearance with PFS compatibility
- Launch of Freedom Infusion System with PFS in targeted markets
- Exploring expansion of oncology strategy in international markets

## Protect and Grow our Core Domestic Business

- 2 new non-Ig drugs on label
  - ✓ UCB RYSTIGGO<sup>®</sup> 510(k) clearance in Jan 2026
  - Roche Phesgo- Submitted 510(k) application in Dec 2025
- 510(k) and MDR submissions Freedom360 (2026)
- 510(k) and global submissions Phase 2 flow controller (2H 2026 - 1H 2027)
- ✓ Outpace SCIg market growth of 8-10%